Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Study Location:

Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL (MK-8591A-054)

A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL (MK-8591A-054)

Not Recruiting

Open to: ALL

Age: 18.0 - N/A

Medical Conditions

Infections
Communicable Diseases


This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


The purpose of this study is to evaluate the safety and tolerability of DOR/ISL in adult participants with HIV-1 who had been previously treated with DOR/ISL in earlier clinical studies. There are no formal hypotheses to be tested in this study.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Mar 2023 Dec 2025

INTERVENTIONAL

Intervention Type : DRUG
Intervention Description : FDC tablet of 100 mg doravirine (DOR)/0.25 mg islatravir (ISL) taken once daily

Intervention Arm Group : DOR/ISL;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • University Hospitals Sussex NHS Foundation Trust ( Site 3004)
    East Sussex
    Brighton And Hove
    BN2 1ES
  • Southmead Hospital ( Site 3003)
    Bristol
    Bristol, City Of
    BS10 5NB
  • Royal Free Hospital ( Site 3002)
    London
    England
    NW32QG
  • King's College Hospital ( Site 3001)
    London
    London, City Of
    SE5 9RL
  • North Manchester General Hospital ( Site 3005)
    Crumpsall
    Manchester
    M8 5RB


The study is sponsored by Merck Sharp & Dohme LLC




We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?

Read full details for Trial ID: NCT05766501
Last updated 07 November 2024

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.